Since NUCB-2 was highly expressed in clinical NPC samples, to further investigate its function on NPC, NUCB-2 knockdown recombinants were established and transferred to the poor-differentiated CNE2 cells, namely, CNE2-KD. Here, NUCB2 is linked to nasopharyngeal carcinoma.